# Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

> **NCT01370135** · NA · COMPLETED · sponsor: **University of Luebeck** · enrollment: 20 (actual)

## Conditions studied

- Neovascular Glaucoma
- Rubeosis

## Interventions

- **DRUG:** 0.5mg intraocular Ranibizumab (Lucentis)

## Key facts

- **NCT ID:** NCT01370135
- **Lead sponsor:** University of Luebeck
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-04
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370135, "Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01370135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*